Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1632
This examiner grants 28% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17914246 | ENTERIC NITRERGIC NEURONS AND METHODS OF USING THE SAME | Non-Final OA | The Regents of the University of California |
| 18806641 | USE OF ADENO-ASSOCIATED VIRAL VECTORS TO CORRECT GENE DEFECTS/ EXPRESS PROTEINS IN HAIR CELLS AND SUPPORTING CELLS IN THE INNER EAR | Final Rejection | Akouos, Inc. |
| 17189376 | NUCLEIC ACID DELIVERY CARRIER, NUCLEIC ACID DELIVERY CARRIER SET, NUCLEIC ACID DELIVERY COMPOSITION, AND NUCLEIC ACID DELIVERY METHOD | Non-Final OA | KABUSHIKI KAISHA TOSHIBA |
| 17772539 | PROTEASE SWITCH FOR DUAL TARGETS CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY | Non-Final OA | THE TEXAS A&M UNIVERSITY SYSTEM |
| 17965656 | COMPOSITIONS FOR PREVENTING OR TREATING DIABETIC SKIN DISEASE COMPRISING EXOSOME-DERIVED FROM THROMBIN-TREATED STEM CELL | Non-Final OA | SAMSUNG LIFE PUBLIC WELFARE FOUNDATION |
| 17429215 | PHARMACEUTICAL COMPOSITION FOR PREVENTING IN-STENT RESTENOSIS | Non-Final OA | Nipro Corporation |
| 18043507 | METHOD OF PRODUCING THREE-DIMENSIONAL TISSUE BODY AND THREE-DIMENSIONAL TISSUE BODY | Non-Final OA | OSAKA UNIVERSITY |
| 17251587 | USE OF FIBROBLASTS AND/OR MODIFIED FIBROBLASTS FOR THREE DIMENSIONAL TISSUE PRINTING | Non-Final OA | Figene, LLC |
| 17761677 | GENE THERAPY COMPOSITION AND TREATMENT OF RIGHT VENTRICULAR ARRYTHMOGENIC CARDIOMYOPATHY | Non-Final OA | UCL BUSINESS LTD |
| 17044779 | NANOPARTICLES FOR GENE EXPRESSION AND USES THEREOF | Non-Final OA | Fred Hutchinson Cancer Center |
| 17461094 | USE OF ENDOTHELIAL PROGENITOR CELLS IN REJUVENATING THE MICROVASCULATURE, PREVENTING AGING AND TREATING AGE-RELATED DISEASES | Non-Final OA | SHENZHEN UNIVERSITY |
| 18183900 | THERAPEUTIC REGENERATIVE CELLS | Non-Final OA | CREATIVE MEDICAL TECHNOLOGIES, INC. |
| 18140060 | Bos GRUNNIENSLNC4047 AND APPLICATION THEREOF | Non-Final OA | LANZHOU INSTITUTE OF HUSBANDRY AND PHARMACEUTICAL SCIENCES OF CAAS. |
| 17543911 | COMPOSITION FOR TREATING INFLAMMATORY DISEASE INDUCED BY HYPERIMMUNE RESPONSE | Final Rejection | KOLON TISSUEGENE, INC. |
| 18130555 | HUMAN UMBILICAL CORD COMPOSITION FOR TREATMENT OF PEYRONIE'S DISEASE | Final Rejection | BioStem Technologies, Inc. |
| 18174853 | METHOD FOR PRODUCING CARTILAGE CELLS INDUCED TO BE DIFFERENTIATED FROM STEM CELLS | Non-Final OA | YiPCELL Inc. |
| 18016513 | METHOD OF CULTURING STEM CELLS | Non-Final OA | SHANGHAI WOLWO STEM CELL TECHNOLOGY CO., LTD. |
| 17143795 | MICROFABRICATED DEVICES AND HIGH THROUGHPUT ASSAYS FOR MODULATORS OF CELL BEHAVIOR | Final Rejection | NOVOHEART INTERNATIONAL LIMITED |
| 17985365 | NOVEL ANUCLEATED CELLS AS A SOURCE FOR TREATMENT OF PLATELET RICH PLASMA DEPENDENT DISORDERS | Non-Final OA | Stellular Bio, Inc. |
| 17423044 | A NOVEL CD16+ NATURAL KILLER CELL AND A METHOD OF CULTURING CD16+ NATURAL KILLER CELL | Non-Final OA | Acepodia Biotechnologies Ltd. |
| 17779326 | 3D HUMAN LIVER ORGAN MODEL CONSTRUCTING METHOD, 3D HUMAN LIVER ORGAN MODEL AND USE THEREOF | Non-Final OA | BEIJING DAXIANG BIOTECH CO., LTD |
| 17771431 | METHODS AND APPARATUS FOR MEASURING IMMUNE MEDIATED TUMOROID RESPONSES | Non-Final OA | VITROSCAN B.V. |
| 17430652 | Use of Haploid Embryonic Cells to Generate Offspring with Predetermined Genomes | Non-Final OA | UNIVERSITÉ DE MONTRÉAL |
| 17582609 | Methods of Cell Renewal | Non-Final OA | CarryGenes Bioengineering, LLC |
| 17602936 | COMPOSITIONS AND METHODS FOR ADMINISTRATION OF THERAPEUTICS | Non-Final OA | Encoded Therapeutics, Inc. |
| 17430623 | CRYOPRESERVATION OF STEM CELLS | Non-Final OA | TiGenix, S.A.U. |
| 17289198 | USE OF AN EGG GRAFTED WITH TUMOR CELLS IN ORDER TO STUDY THE ANTI-CANCER EFFECTIVENESS OF IMMUNE THERAPIES IN THE ABSENCE OF IMMUNE EFFECTOR CELLS OTHER THAN THOSE IN THE GRAFTED EGG | Final Rejection | INOVOTION |
| 17268023 | COMPOSITION FOR IMPROVED BONE FRACTURE HEALING | Non-Final OA | CORTHOTEC LTD |
| 15766792 | NEURAL PRECURSOR CELL POPULATIONS AND USES THEREOF | Final Rejection | Neurona Therapeutics Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy